These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37747726)

  • 1. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
    Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
    Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes.
    Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.
    Ishi Y; Zhang Y; Zhang A; Sasaki T; Piunti A; Suri A; Watanabe J; Abe K; He X; Katagi H; Bhalla P; Natsumeda M; Zou L; Shilatifard A; Hashizume R
    Mol Cancer Ther; 2022 May; 21(5):715-726. PubMed ID: 35247919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
    Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
    Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
    Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
    Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer.
    Kazansky Y; Kentsis A
    Cancer Res; 2023 Dec; 83(23):3827-3829. PubMed ID: 38037453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
    Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
    J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
    Wang R; You J
    J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.
    Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA
    Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.
    Zhang H; Zhu D; Zhang Z; Kaluz S; Yu B; Devi NS; Olson JJ; Van Meir EG
    Oncogene; 2020 Jan; 39(5):1041-1048. PubMed ID: 31582835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Ezh2 redistributes bivalent domains within transcriptional regulators associated with WNT and Hedgehog pathways in osteoblasts.
    Carrasco ME; Thaler R; Nardocci G; Dudakovic A; van Wijnen AJ
    J Biol Chem; 2023 Sep; 299(9):105155. PubMed ID: 37572850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
    Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
    Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
    Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
    Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
    Huang N; Liao P; Zuo Y; Zhang L; Jiang R
    J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
    Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
    Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.